Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Novel Endometrial Cancer Models Using Sensitive Metastasis Tracing for CXCR4-Targeted Therapy in Advanced Disease

  • Medina-Gutiérrez, Esperanza
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Rioja Blanco, Elisa|||0000-0003-4176-8772
  • Pavón, Miguel Àngel
  • Asensio-Puig, Laura|||0000-0003-1772-1923
  • Farré, Lourdes|||0000-0002-3168-1940
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
Advanced endometrial cancer (EC) lacks therapy, thus, there is a need for novel treatment targets. CXCR4 overexpression is associated with a poor prognosis in several cancers, whereas its inhibition prevents metastases. We assessed CXCR4 expression in EC in women by using IHC. Orthotopic models were generated with transendometrial implantation of CXCR4-transduced EC cells. After in vitro evaluation of the CXCR4-targeted T22-GFP-H6 nanocarrier, subcutaneous EC models were used to study its uptake in tumor and normal organs. Of the women, 91% overexpressed CXCR4, making them candidates for CXCR4-targeted therapies. Thus, we developed CXCR4 EC mouse models to improve metastagenesis compared to current models and to use them to develop novel CXCR4-targeted therapies for unresponsive EC. It showed enhanced dissemination, especially in the lungs and liver, and displayed 100% metastasis penetrance at all clinically relevant sites with anti-hVimentin IHC, improving detection sensitivity. Regarding the CXCR4-targeted nanocarrier, 60% accumulated in the SC tumor; therefore, selectively targeting CXCR4 cancer cells, without toxicity in non-tumor organs. Our CXCR4 EC models will allow testing of novel CXCR4-targeted drugs and development of nanomedicines derived from T22-GFP-H6 to deliver drugs to CXCR4 cells in advanced EC. This novel approach provides a therapeutic option for women with metastatic, high risk or recurrent EC that have a dismal prognosis and lack effective therapies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Industrial By-Products As a Novel Circular Source of Biocompatible Extracellular Vesicles

  • Lorca, Cristina
  • Laparra, Moisés
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Casaní, Laura|||0000-0002-0139-4588
  • Florit, Sergi
  • Jové, Mariona|||0000-0001-5577-6162
  • Mota-Martorell, Natàlia|||0000-0001-5937-7070
  • Vilella, Elisabet|||0000-0002-1887-5919
  • Gallart-Palau, Xavier
  • Serra, Aida
Extracellular vesicles (EVs) constitute an intricate system of molecular exchange that has recently gained tremendous interest. However, sustainable sources of safe biological EVs remain scarce and elusive. This study explores and defines the use of food industry by-products (BP) as a circular source of safe biocompatible EVs. Averaged diameter and molecular compositions indicate a large yield of exosomes and high abundancy of membrane lipids with signaling capacity in these vesicles. Complex proteomes mimicking those circulating in human blood plasma are also identified. Furthermore, BP-EVs do not show relevant cytotoxicity and display excellent oral and intravenous bioavailability together with specific organ targeting capacity. Collectively, it is believed that the novel findings reported here will open substantial venues for the use of BP as an optimal source of biocompatible nanovesicles in manifold applications of the biotechnological and biomedical fields.